AR062426A1 - Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor. - Google Patents

Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor.

Info

Publication number
AR062426A1
AR062426A1 ARP070103674A ARP070103674A AR062426A1 AR 062426 A1 AR062426 A1 AR 062426A1 AR P070103674 A ARP070103674 A AR P070103674A AR P070103674 A ARP070103674 A AR P070103674A AR 062426 A1 AR062426 A1 AR 062426A1
Authority
AR
Argentina
Prior art keywords
alkyl
twice
group
substituted
substituted once
Prior art date
Application number
ARP070103674A
Other languages
English (en)
Inventor
Annette Schuler-Metz
Rainer Walter
Iris Kauffmann-Hefner
Heiner Ebel
Angelo Ceci
Ingo Konetzki
Norbert Hauel
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR062426A1 publication Critical patent/AR062426A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de la formula general (1), R5-A-R4-B-R3-A-D-Y-N(R2)SO2-R1 en la que A significa un enlace o -alquileno C1-4 o -CH2-C(O)-, B significa un enlace, -alquileno C1-3, -O- o -C(O)-, D significa un grupo de las formulas generales 2, Y significa un grupo -alquileno C1-6, eventualmente sustituido con el radical R2, en donde un grupo metileno puede estar reemplazado adicionalmente por Y1 e Y1 representa -O-, -S-, -S(O) -, -N(R2)-, -N(R2)-C(O)-, -C(O)-N(R2), -C(O)-, -CH(arilo)-, cicloalquileno C3-6 o -S(O)2-, R1 significa cicloalquilo C3-7- o arilo, heteroarilo- o arilalquilo C1-3-, que en cada caso pueden estar sustituidos con uno, dos, tres o cuatro radicales R1.1, en donde los radicales R1.1, pueden ser iguales o diferentes, y R1.1 representa H, F, Cl, Br, I, alquilo C1-3-, F3C-, HO-, alquil C1-3-O o alquil C1-3-O-alquilen C2-4-O-, R2 significa H o alquilo C1-3, en donde cada grupo metileno puede estar sustituido con hasta dos y cada grupo metilo puede estar sustituido con hasta tres átomos de fluoro, o también H3C-C(O)-, R3 significa a) -alquileno C1-6, b) un grupo cicloalquileno C3-6, sustituido una vez, dos o tres veces con R3.1, c) un grupo cicloalquenileno C3-6, sustituido una vez o dos veces con R3.1, que está condensado con un anillo de fenilo a través del enlace insaturado, d) -N(R3)-, e) un grupo arileno sustituido una vez o dos veces con R3.1, f) un grupo heteroarileno sustituido una vez o dos veces con R3.1, g) un anillo heterocíclico de 4 a 7 miembros, saturado, sustituido una o dos veces con R3.1, h) un anillo heterocíclico de 5 a 7 miembros, insaturado, sustituido una o dos veces con R3.1, que está condensado a través de los enlaces insaturados con uno o dos anillos de fenilo o i) un aza-heterobiciclo de 8 a 10 miembros, saturado, sustituido una o dos veces con R3.1, en donde los radicales R3.1 pueden en cada caso ser iguales o diferentes y R3.1 representa H, F, Cl, Br, I, alquilo C1-3-, HO-, alquil C1-3-O- o alquil C1-3-O- alquilen C2-4-O-, o R3 significa también -O-, cuando B no representa el grupo -O-, R4 significa a) -O-, b) -C(O)O-, c) -C(O)NR2-, d) -NR2-, e) -NR2-NR2-, f) -cicloalquileno C3-7, g) -alquileno C1-6, h) un grupo arileno, sustituido una vez o dos veces con R4.1, i) un grupo heteroarileno sustituido una vez o dos veces con R4.1, j) un anillo heterocíclico de 4 a 7 miembros, saturado, sustituido una o dos veces con R3.1, k) un diaza-heterobiciclo de 8 a 10 miembros, saturado, sustituido una o dos veces con R4.1, l) un anillo heterocíclico de 5 a 7 miembros, insaturado, sustituido una o dos veces con R4.1, que está condensado a través de los enlaces insaturados con uno o dos anillos de fenilo o m) un diaza-espirociclo de 9 a 11 miembros, saturado, en donde los radicales R4.1 pueden en cada caso ser iguales o diferentes y R4.1 representa H, F, Cl, Br, I, alquilo C1-3-, HO-, alquil C1-3-O- o alquil C1-3-O-alquilen C2-4-O-, R5 significa H, HO-, alquilo C1-8, un grupo cicloalquilo C3-7 eventualmente sustituido con alquilo C1-3-, H2N-, alquil C1-4-NH-, cicloalquil C1-4-NH-, (alquilo C1-4)2N-, (alquil C1-4) (cicloalquil C3-6)N-, (ciclopropilmetil)(metil)N-, H2N-C(O)-, un grupo fenilo sustituido una o dos veces con R5.1, un grupo heteroarilo sustituido una o dos veces con R5.1o un anillo heterocíclico de 4 a 7 miembros, saturado, sustituido una o dos veces con R5.1, en donde los radicales R5.1 pueden en cada caso ser iguales o diferentes y R5.1 representa H, F, Cl, Br, I, alquilo C1-3-, HO-, alquil C1-3-O-, (alquil C1-3)2N- o alquil C1-3-O-alquilen C2-4-O-, sus enantiomeros, sus diastereoisomeros, sus mezclas y sus sales, en particular sus sales fisiologicamente compatibles con ácidos o bases orgánicos o inorgánicos, medicamentos que contienen los compuestos farmacologicamente activos y su preparacion y uso.
ARP070103674A 2006-08-19 2007-08-17 Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor. AR062426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006039003A DE102006039003A1 (de) 2006-08-19 2006-08-19 Neue Verbindungen

Publications (1)

Publication Number Publication Date
AR062426A1 true AR062426A1 (es) 2008-11-05

Family

ID=38925625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103674A AR062426A1 (es) 2006-08-19 2007-08-17 Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor.

Country Status (20)

Country Link
US (2) US7858618B2 (es)
EP (3) EP2284166B1 (es)
JP (3) JP5291623B2 (es)
KR (1) KR20090047535A (es)
CN (1) CN101516867A (es)
AR (1) AR062426A1 (es)
AU (1) AU2007287652A1 (es)
BR (1) BRPI0715645A2 (es)
CA (1) CA2663598A1 (es)
CL (1) CL2007002407A1 (es)
CO (1) CO6160230A2 (es)
DE (1) DE102006039003A1 (es)
EA (1) EA200900279A1 (es)
IL (1) IL197021A0 (es)
MX (1) MX2009001791A (es)
NO (2) NO20090079L (es)
SG (3) SG169338A1 (es)
TW (1) TW200815394A (es)
WO (1) WO2008022945A1 (es)
ZA (1) ZA200810782B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
WO2010017850A1 (de) * 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von cycloalkyl-substituierten piperazinverbindungen
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
JP2011512329A (ja) * 2008-02-06 2011-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有効な鎮痛剤としてのアリールスルホンアミド
PE20091782A1 (es) * 2008-04-08 2009-11-15 Gruenenthal Chemie Derivados de sulfonamida sustituida
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
KR20110036044A (ko) * 2008-07-18 2011-04-06 다케다 파머수티컬 컴패니 리미티드 벤즈아제핀 유도체들 및 히스타민 h3 길항제로서 이들의 용도
US8207335B2 (en) * 2009-02-13 2012-06-26 Boehringer Ingelheim International Gmbh Process for making certain compounds having B1 antagonistic activity
EP2616073A4 (en) * 2010-09-13 2015-02-18 Microbiotix Inc INHIBITORS OF IMMERSION OF VIRUSES IN MAMMALIAN HOST CELLS
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
KR101735705B1 (ko) 2015-09-22 2017-05-15 주식회사 에코시안 건물 에너지 효율화 평가 방법 및 장치
CN105153168A (zh) * 2015-09-29 2015-12-16 上海天慈国际药业有限公司 N-[4-(2-甲基-4,5-二氢-3H-咪唑并[4,5-d][1]苯并氮杂卓-6-甲酰基)苯基]-2-苯基苯甲酰胺盐酸盐的制备方法
KR101645157B1 (ko) 2015-11-10 2016-08-02 주식회사 넥스미디어 통합 음식 제공 서비스 방법 및 장치
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Prmt5阻害剤としてのヘテロ環式化合物
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1100635B (de) 1958-04-22 1961-03-02 Rhone Poulenc Sa Verfahren zur Herstellung von Phenthiazinderivaten
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
KR100733752B1 (ko) 1999-11-26 2007-06-29 시오노기세이야쿠가부시키가이샤 Npyy5 길항제
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
JP2006516132A (ja) 2002-12-19 2006-06-22 エラン ファーマシューティカルズ,インコーポレイテッド 置換n−フェニルスルホンアミドブラジキニン拮抗薬
AU2004226197B2 (en) * 2003-03-25 2009-12-03 Laboratoires Fournier S.A. Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
CA2553676A1 (en) * 2004-01-28 2005-08-11 Research Development Foundation Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
AU2005289881A1 (en) * 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
WO2006035967A1 (en) 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060217362A1 (en) 2004-12-29 2006-09-28 Tung Jay S Novel compounds useful for bradykinin B1 receptor antagonism
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
CA2696302A1 (en) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh New compounds
WO2009021944A1 (de) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Neue verbindungen
DE102007046887A1 (de) * 2007-09-28 2009-04-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen

Also Published As

Publication number Publication date
EP2061779B1 (de) 2013-11-06
US20090137545A1 (en) 2009-05-28
KR20090047535A (ko) 2009-05-12
NO20090079L (no) 2009-02-16
JP5650781B2 (ja) 2015-01-07
WO2008022945A1 (de) 2008-02-28
EP2284166A1 (de) 2011-02-16
CO6160230A2 (es) 2010-05-20
DE102006039003A1 (de) 2008-02-21
US7858618B2 (en) 2010-12-28
TW200815394A (en) 2008-04-01
EP2402329A1 (de) 2012-01-04
BRPI0715645A2 (pt) 2013-07-09
AU2007287652A1 (en) 2008-02-28
JP2013177392A (ja) 2013-09-09
JP5291623B2 (ja) 2013-09-18
CL2007002407A1 (es) 2009-03-27
JP2012149086A (ja) 2012-08-09
NO20091025L (no) 2009-03-09
EP2402329B1 (de) 2013-05-22
EA200900279A1 (ru) 2009-10-30
SG169337A1 (en) 2011-03-30
MX2009001791A (es) 2009-03-02
JP5529202B2 (ja) 2014-06-25
CA2663598A1 (en) 2008-02-28
ZA200810782B (en) 2009-11-25
EP2284166B1 (de) 2013-10-16
SG169338A1 (en) 2011-03-30
IL197021A0 (en) 2009-11-18
CN101516867A (zh) 2009-08-26
EP2061779A1 (de) 2009-05-27
SG169339A1 (en) 2011-03-30
US8252785B2 (en) 2012-08-28
US20110021488A1 (en) 2011-01-27
JP2010501514A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
AR062426A1 (es) Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor.
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR053344A1 (es) Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR046600A1 (es) Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8
SV2007002359A (es) Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada ref. bhco 41331/sv
AR054188A1 (es) Aminas ciclicas con actividad inhibitoria del factor de coagulacion xa, metodos para su sintesis, intermediarios del proceso de obtencion de las mismas y su elaboracion, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del a
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AR048340A1 (es) Compuestos de acido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por orl1.
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
AR061629A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR067927A1 (es) Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR055344A1 (es) Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38
UY28787A1 (es) Derivados de beta-aminoacidos como inhibidores del factor xa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal